Investor Presentation
131
Investor presentation First six months of 2022
North America Operations at a glance.
NAO
Diabetes trend in population
Diabetes market by value and
Novo Nordisk market share
Novo Nordisk reported sales
Million
DKK
billion
First half of 2022
Sales
(mDKK)
Growth²
70
10%
600
80%
Total GLP-13
24,638
41%
60
11%
Long-acting insulin4
2,880
-22%
50
60%
Premix insulin5
271
-11%
400
36.8%¹
GLP-1
Fast-acting insulin
3,040
-16%
40
Human insulin
788
-3%
40%
30
63
Total insulin
6,979
-18%
57
51
1.4%1
Insulin
20
20
200
Other Diabetes care?
383
-29%
20%
10
13.2%1
OAD
Diabetes care
Obesity care
32,000
21%
4,565
102%
0
2021
0
0%
Diabetes & Obesity
May
2030
2045
2017
Population with diabetes
Diabetes growth rate
GLP-1 MS
Insulin MS
May
2022
OAD MS
36,565
27%
care
Rare disease⁹
4,128
-1%
Total
40,693
24%
International Diabetes Federation: Diabetes Atlas 1th Edition
2000 and Diabetes Atlas 10th Edition 2021
1 CAGR calculated for 5-year period
Competitor insulin value market shares, as of May 2022: Novo
Nordisk 42%, Eli Lilly 30% and Sanofi 27%; Competitor GLP-1
value market shares, as of May 2022: Novo Nordisk 53%, Eli Lilly
44% and AstraZeneca 3%
OAD: Oral anti-diabetic; MS: Market Share; Source: IQVIA MAT,
May 2022 value figures
2 At constant exchange rates; 3 Comprises Victoza®, Ozempic®, and RybelsusⓇ;
4 Comprises Tresiba®, XultophyⓇ and LevemirⓇ: 5 Comprises NovoMix®;
6 Comprises FiaspⓇ and NovoRapidⓇ; 7 Comprises Novo NormⓇ and needles; 8
Comprises SaxendaⓇ and Wegovy 9 Comprises primarily NovoSevenⓇ,
NovoEight® Esperoct®, NovoThirteen®, Refixia®, Norditropin®, VagifemⓇ and
Activelle®
Source: Quarterly company announcementView entire presentation